HEALTH

Crown Labs buys 5 brands from GSK

BY David Salazar

Johnson City, Tenn.-based Crown Labs has added several OTC brands to its portfolio. The company purchased the North American distribution rights for acne wash PanOxyl, anti-itch lotion Sarna, antifungal Zeasorb, antifungal powder Desenex and pain-relief gel Mineral Ice from GlaxoSmithKline.

“Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” said Jeff Bedard, Crown Labs president and CEO. “I am especially excited to bring the Stiefel brands to Crown as I personally enjoyed tremendous success in marketing them as a field sales representative for Stiefel in the ’80s and ’90s.”

Crown Labs, a Hildred Capital Partners Portfolio company, and partner David Solomon, who also is chairman of Crown Labs, said, “The addition of these brands provides meaningful diversification for our OTC portfolio and enhances our breadth of trusted consumer skin care therapies. We will continue to look for interesting opportunities to build on Crown’s consumer healthcare, aesthetic and prescription product lines.”

Crown Labs has selected the Emerson group to manage the sales activity and logistics of the products.

“We are extremely excited to partner with Crown Laboratories,” said Scott Emerson, chairman and CEO of the Emerson Group. “Crown’s management team, dermatology expertise and enhanced resources will serve the acquired brands well in a very attractive growth category for our retailers.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
higi bridge connector
HEALTH

New higi partnership opens doors to patient data

BY David Salazar

Population health enablement company higi has unveiled a partnership with Bridge connector, a company that offers streamlined integration solutions for healthcare organizations. The partnership, the companies said, will allow for integration between higi health stations using Health Connect and any electronic health record or hospital health system using Bridge connector.

“With over 52 million total users, higi is the leading health platform for engaging with consumers where they are. The power in our platform comes when we remove the friction between connecting the consumer with their trusted healthcare provider to allow the consumer to consent and share their data in real-time to enable additional touchpoints and timely interventions,” said higi CEO Jeff Bennett. “With Bridge Connector, we continue to make it easier for consumers to be their healthiest by making health care better connected.”

Bridge Connector and higi said that the collaboration opened the door for higi’s platform to connect with providers, payers, employers, retailers and others looking to manage patient data. Patients use higi’s roughly 11,000 health stations in retail locations close to a million times weekly, higi said.

“By partnering with higi, we are creating an ecosystem where consumers are finally being put at the center of their own care, enabling millions of patients — every year — to determine how their personal data flows,” said David Wenger, CEO and founder of Bridge Connector. “With easier access to their health information, they’re empowered to make more informed decisions, and this partnership furthers our vision for improving healthcare communication towards complete interoperability.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
P&G world headquarters
HEALTH

P&G closes buy of Merck KGaA’s consumer health business

BY DSN STAFF

Procter & Gamble now has a larger consumer brand portfolio and geographic scale. The company announced Friday that it had completed its €3.2 billion acquisition of Darmstadt, Germany-based Merck KGaA’s consumer health business.

The company said the acquisition increases its footprint in most of the world’s top 15 OTC markets. Top brands that join the Cincinnati-based company’s portfolio include Neurobion, Dolo-Neurobion, Femibion, Nasivin, Bion3, Seven Seas and Kytta — all of which are sold largely in Europe, Latin America and Asia.

As part of the acquisition, Merck KGaA’s Uta Kemmerich-Keil — formerly president and CEO — joins P&G as the leader of P&G Personal Healthcare International, an organization that encompasses the newly combined OTC business in Europe, Latin America and Asia, as well as India, the Middle East and Africa.

“Today marks the beginning of an exciting new era for P&G Personal Health Care, as we now move forward to realize the great potential of our combined businesses,” said Tom Finn, president of P&G Global Personal Health Care. “In bringing Merck KGaA, Darmstadt, Germany, Consumer Health into P&G, we have created a new healthcare organization that is well-positioned to enable consumers to live longer, healthier and more vibrant lives, as well as drive further sales and profit growth for P&G.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?